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Background: As waiting times for cardiac transplant have increased, ventricular assist devices (VAD) have become critical for “bridging” patients 
with end-stage heart failure. Most reported post-discharge experience is with left ventricular assist devices (LVAD). We sought to evaluate the safety 
and efficacy of home discharge on biventricular assist devices (BIVAD) compared to LVAD.
Methods: We retrospectively reviewed the hospital course and post-discharge outcomes of 39 consecutive patients implanted with Thoratec 
paracorporeal VADs as bridge to transplant from 2/04 to 7/08. Twenty-six (67%) patients were successfully transferred from the ICU and considered 
candidates for discharge. Post-discharge safety was assessed in the context of frequency and reasons for hospital readmission. Overall survival was 
evaluated to compare the relative effectiveness of LVAD versus BIVAD.
Results: Of 26 patients, 4 (15%) were not discharged for psychosocial reasons (2), VT/VF (1), and stroke (1). Twenty-two (85%) patients were 
discharged home: 12 BIVAD, 10 LVAD. Total days at home were 1909 (863 and 1046 days for BIVAD and LVAD, respectively), with a median of 59 
days for the entire cohort. There were 23 readmissions in 14 patients: 15 in BIVAD patients, 8 in LVAD patients for cumulative length of stay of 300 
and 128 days, respectively. Median number of readmissions for both BIVAD and LVAD patients was 1. The two most common causes of readmission 
were stroke/TIA (BIVAD 2, LVAD 3) and device malfunction (BIVAD 4, LVAD 0). All device malfunctions required prolonged hospitalization, but 
resulted in transplant. Of the discharged patients, 9 of 12 (75%) BIVAD and 7 of 10 (70%) LVAD experienced successful outcomes (15 transplants; 1 
BIVAD explant). Overall post-discharge survival rate was 82%.
Conclusions: Patients with end-stage heart failure bridging to transplant can be safely discharged home on BIVAD, and demonstrate readmission 
and survival rates comparable to LVAD. For patients demonstrating device competency and adequate home support, discharge should be the goal 
regardless of type of VAD.
